Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 20 peer-reviewed journal articles Updated
Pediatric Surgery

Standard of Care Treatment for Cystinosis

At a Glance

The standard of care for cystinosis requires a lifelong commitment to systemic cysteamine therapy to remove toxic cystine from cells. Treatment also involves nutritional supplements, topical eye drops to protect vision, and often G-tubes or kidney transplants to manage organ damage.

Managing cystinosis requires a lifelong commitment to a multi-layered treatment plan. While the diagnosis is complex, the standard of care is well-established and focused on two main goals: removing trapped cystine from the cells and replacing the nutrients the kidneys are losing [1][2].

Systemic Therapy: Cysteamine

The most critical part of treatment is systemic cystine-depleting therapy using a medication called cysteamine bitartrate [1]. This medication acts like a “key” that opens the locked doors of the lysosomes, allowing the trapped cystine to escape [3].

There are two main types of oral cysteamine:

  • Immediate-Release (e.g., Cystagon): This formulation must be taken every 6 hours, including through the night [4].
  • Delayed-Release (e.g., Procysbi): This formulation is designed to be taken every 12 hours, which can make daily life and sleep schedules much easier for families [5][4].

Managing the Realities of Cysteamine

While cysteamine is life-saving, it comes with severe side effects that are often the hardest part of the journey [6].

  • Gastrointestinal Distress: Cysteamine heavily increases stomach acid, causing severe nausea, vomiting, and abdominal pain. This is usually managed by prescribing acid-reducing medications, such as proton pump inhibitors (PPIs), alongside the cysteamine [6].
  • Sulfurous Odor: The medication breaks cystine down into a compound that produces a strong sulfur or “rotten egg” smell on the breath and through the sweat pores [6]. This is a normal, though challenging, part of treatment that can be somewhat mitigated by strictly following dosing schedules with your doctor or managing diet.

Important Note: While cysteamine is highly effective at protecting most organs, it generally does not cure Fanconi syndrome (the “leaky” kidneys) [2][7].

Managing Fanconi Syndrome & The Role of Feeding Tubes

Because the kidneys are losing vital nutrients through the urine, your child will likely need a customized “cocktail” of supplements (like bicarbonate, citrate, phosphate, and potassium) [8][2]. They also need to replace the massive amounts of water lost.

The Reality for Infants: Expecting a baby or toddler to voluntarily drink massive volumes of water mixed with foul-tasting, salty supplements is often impossible and sets families up for daily battles. For this reason, doctors frequently recommend placing a Gastrostomy tube (G-tube) directly into the stomach [9]. A G-tube is an incredibly positive, stress-relieving tool. It ensures your child stays hydrated, receives exact medication doses, and gets necessary nutrition while they sleep, completely removing the stress of forced oral feeding [9].

Protecting the Eyes: Topical Drops

Oral cysteamine does not reach the cornea (the front of the eye) effectively [10]. Therefore, your child will also need topical cysteamine eye drops to dissolve the crystals that form there [11][12].

  • The Schedule: These drops are intensive. Standard liquid formulations often need to be administered every waking hour, while newer gel drops can be given a few times a day. Consistent use is essential to prevent severe light sensitivity and maintain clear vision [13][14].

Kidney Transplantation

For many children with the infantile form, the kidneys will eventually lose their ability to filter blood despite treatment.

  • The Timeline: With early and strict cysteamine therapy, kidney failure can often be successfully delayed until late childhood, the teenage years, or even early adulthood [15][11].
  • The Outcome: Kidney transplants are highly successful in patients with cystinosis [16][17]. Because cystinosis is a systemic disease, the new kidney does not have the genetic defect and will not develop Fanconi syndrome [16].
  • The Catch: While the transplant fixes the kidney failure, it does not fix the cystinosis in the rest of the body [18]. Your child must continue taking oral cysteamine and eye drops after the transplant to protect their other organs [16][19].

The Future: Gene Therapy and Research

We are currently in a hopeful era of research. Scientists are exploring gene therapy, where a patient’s own stem cells are modified to produce functional cystinosin and given back to them [NCT06910813][20]. Clinical trials (like CTNS-RD-04) are testing whether this one-time treatment can stop cystine accumulation without the need for daily oral medication [NCT06910813][20].

Common questions in this guide

What is the standard treatment for cystinosis?
The primary treatment is systemic cystine-depleting therapy using a medication called cysteamine bitartrate. This acts like a key to unlock cells and allow trapped cystine to escape, which protects the body's organs from long-term damage.
What is the difference between immediate-release and delayed-release cysteamine?
Immediate-release formulations must be taken every 6 hours, which requires waking up during the night. Delayed-release options are designed to be taken every 12 hours, which can significantly improve daily routines and sleep schedules for families.
How do we manage the stomach upset and nausea caused by cysteamine?
Cysteamine significantly increases stomach acid, which often leads to severe nausea, vomiting, and abdominal pain. Doctors typically prescribe acid-reducing medications, such as proton pump inhibitors (PPIs), to take alongside cysteamine to manage these side effects.
Why might my child need a G-tube for cystinosis?
Children with cystinosis lose massive amounts of water and nutrients through their kidneys and often struggle to drink enough foul-tasting supplements. A G-tube removes the stress of forced feeding by ensuring the child receives exact medication doses, hydration, and nutrition directly into the stomach.
Why are cysteamine eye drops necessary if my child takes oral medication?
Because oral cysteamine does not effectively reach the front of the eye, topical cysteamine eye drops are required. These specialized drops dissolve the cystine crystals that form in the cornea, which helps prevent severe light sensitivity and keeps vision clear.
Will a kidney transplant cure my child's cystinosis?
While a transplant successfully cures the kidney failure and the nutrient-wasting Fanconi syndrome, it does not cure cystinosis in the rest of the body. Your child must continue taking oral cysteamine and eye drops after the transplant to protect their other organs from cystine buildup.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Should we start with immediate-release or delayed-release cysteamine, and what are the pros and cons for my child's daily schedule?
  2. 2.What acid-reducing medications (like PPIs) do you recommend to help manage the stomach upset from cysteamine?
  3. 3.Can we speak with a pediatric surgeon or gastroenterologist about placing a G-tube to relieve the stress of oral feeding?
  4. 4.When should my child begin using cysteamine eye drops, and exactly how many times per day must they be administered?
  5. 5.Is my child currently a candidate for any clinical trials, such as the gene therapy trials?
  6. 6.At what age or kidney function level should we realistically begin discussing the process of kidney transplantation?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (20)
  1. 1

    An international cohort study spanning five decades assessed outcomes of nephropathic cystinosis.

    Emma F, Hoff WV, Hohenfellner K, et al.

    Kidney international 2021; (100(5)):1112-1123 doi:10.1016/j.kint.2021.06.019.

    PMID: 34237326
  2. 2

    Management of bone disease in cystinosis: Statement from an international conference.

    Hohenfellner K, Rauch F, Ariceta G, et al.

    Journal of inherited metabolic disease 2019; (42(5)):1019-1029 doi:10.1002/jimd.12134.

    PMID: 31177550
  3. 3

    Structural basis for proton coupled cystine transport by cystinosin.

    Löbel M, Salphati SP, El Omari K, et al.

    Nature communications 2022; (13(1)):4845 doi:10.1038/s41467-022-32589-2.

    PMID: 35977944
  4. 4

    Cysteamine bitartrate delayed-release capsules control leukocyte cystine levels and promote statural growth and kidney health in an open-label study of treatment-naïve patients <6 years of age with nephropathic cystinosis.

    Vaisbich MH, Caires Ferreira J, Price H, et al.

    JIMD reports 2022; (63(1)):66-79 doi:10.1002/jmd2.12260.

    PMID: 35028272
  5. 5

    Local Guidance on the Management of Nephropathic Cystinosis in the Gulf Cooperation Council (GCC) Region.

    Aleid H, AlShareef T, Kaddourah A, et al.

    Children (Basel, Switzerland) 2025; (12(8)) doi:10.3390/children12080992.

    PMID: 40868444
  6. 6

    Therapeutic strategies in cystinosis: A focus on cysteamine and beyond.

    Santoro A, Ferrara YV, De Angelis A

    Experimental and molecular pathology 2025; (144()):104995 doi:10.1016/j.yexmp.2025.104995.

    PMID: 40912033
  7. 7

    Nephropathic Cystinosis: Symptoms, Treatment, and Perspectives of a Systemic Disease.

    Bäumner S, Weber LT

    Frontiers in pediatrics 2018; (6()):58 doi:10.3389/fped.2018.00058.

    PMID: 29594088
  8. 8

    An Extremely Low-Birth-Weight Infant With Bone Fragility Due to Fanconi Syndrome.

    Yoshida R, Hosokawa M, Ukawa T, et al.

    Kidney medicine 2026; (8(2)):101227 doi:10.1016/j.xkme.2025.101227.

    PMID: 41623299
  9. 9

    Body growth, upper arm fat area, and clinical parameters in children with nephropathic cystinosis compared with other pediatric chronic kidney disease entities.

    Kluck R, Müller S, Jagodzinski C, et al.

    Journal of inherited metabolic disease 2022; (45(2)):192-202 doi:10.1002/jimd.12473.

    PMID: 34989402
  10. 10

    Diagnosis of Nephropathic Cystinosis in a Child During Routine Eye Exam.

    Ecel M, Sarı A, Delibaş A

    Turkish journal of ophthalmology 2017; (47(5)):292-295 doi:10.4274/tjo.69922.

    PMID: 29109899
  11. 11

    Ocular Complications of Infantile Nephropathic Cystinosis.

    Bishop R

    The Journal of pediatrics 2017; (183S()):S19-S21 doi:10.1016/j.jpeds.2016.12.055.

    PMID: 28343471
  12. 12

    Shimmering Clarity: A Rare Case Report of Ocular Cystinosis.

    Angadi AM, Jakhalu K, Mushtaq I, Shah S

    Case reports in ophthalmology 2025; (16(1)):847-855 doi:10.1159/000548833.

    PMID: 41321547
  13. 13

    Phenotypic variability in cystinosis: Lessons from an atypical case.

    Toso D, Furlano M, Tinoco A, et al.

    Nefrologia 2025; (45(7)):501342 doi:10.1016/j.nefroe.2025.501342.

    PMID: 41005824
  14. 14

    Photophobia and corneal crystal density in nephropathic cystinosis: an in vivo confocal microscopy and anterior-segment optical coherence tomography study.

    Liang H, Baudouin C, Tahiri Joutei Hassani R, et al.

    Investigative ophthalmology & visual science 2015; (56(5)):3218-25 doi:10.1167/iovs.15-16499.

    PMID: 26024106
  15. 15

    Relationship between age at initiation of cysteamine treatment, adherence with therapy, and glomerular kidney function in infantile nephropathic cystinosis.

    Nießl C, Boulesteix AL, Oh J, et al.

    Molecular genetics and metabolism 2022; (136(4)):268-273 doi:10.1016/j.ymgme.2022.06.010.

    PMID: 35835062
  16. 16

    Cystinosis in Pediatric Renal Transplant Recipients: A Case-Control Study From Kuwait.

    Gheith O, Nair P, Adel M, et al.

    Experimental and clinical transplantation : official journal of the Middle East Society for Organ Transplantation 2022; (20(Suppl 1)):95-99 doi:10.6002/ect.MESOT2021.P40.

    PMID: 35384816
  17. 17

    Native kidney and graft survival in a cohort of Egyptian children with nephropathic cystinosis: national referral center experience.

    Helmy R, Atia FM, Soliman NA

    Italian journal of pediatrics 2025; (51(1)):110 doi:10.1186/s13052-025-01943-7.

    PMID: 40197488
  18. 18

    Clinical myopathy in patients with nephropathic cystinosis.

    Sadjadi R, Sullivan S, Grant N, et al.

    Muscle & nerve 2020; (61(1)):74-80 doi:10.1002/mus.26726.

    PMID: 31588568
  19. 19

    An Isogenic Human Myoblast Cell Model for Cystinosis Myopathy Reveals Alteration of Key Myogenic Regulatory Proteins.

    Medaer L, Mora R, Zhou Z, et al.

    Journal of cachexia, sarcopenia and muscle 2025; (16(6)):e70116 doi:10.1002/jcsm.70116.

    PMID: 41208577
  20. 20

    Hematopoietic Stem-Cell Gene Therapy for Cystinosis.

    Barshop BA, Ball ED, Benador N, et al.

    The New England journal of medicine 2026; (394(8)):753-762 doi:10.1056/NEJMoa2506431.

    PMID: 41707137

This page provides educational information about the standard of care treatments for cystinosis. Always consult your pediatric nephrologist or healthcare team before modifying your child's medication or care routine.

Get notified when new evidence is published on Cystinosis.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.